Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111In-DOTA-Gly3Phe-m170
- Development stage
- Unknown
- Lead developer
- University of California, Davis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
111In-DOTA-Gly3Phe-m170 is a radiolabeled monoclonal antibody conjugate developed for the imaging and radioimmunotherapy of epithelial cancers, particularly breast and prostate adenocarcinomas. It comprises the m170 monoclonal antibody, which recognizes a panadenocarcinoma antigen, linked to the chelator DOTA (1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) via a specialized peptide linker, Gly3Phe (glycylglycylglycyl-phenylalanine). The conjugate is labeled with the radionuclide Indium-111 (111In), allowing for SPECT imaging to evaluate tumor localization and pharmacokinetics. Research has indicated that its tumor uptake may be enhanced when administered in sequence with taxanes like paclitaxel, which may synergize the therapeutic effect of radiolabeled antibodies.
- Other names
- Indium-111 DOTA-Gly3Phe-m170Indium111 DOTA-Gly3Phe-m170Indium 111 DOTA-Gly3Phe-m170111In-m170
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on 111In-DOTA-Gly3Phe-m170.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111In-DOTA-Gly3Phe-m170.